Your browser doesn't support javascript.
loading
LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells.
Serra-Bardenys, Gemma; Blanco, Enrique; Escudero-Iriarte, Carmen; Serra-Camprubí, Queralt; Querol, Jessica; Pascual-Reguant, Laura; Morancho, Beatriz; Escorihuela, Marta; Tissera, Natalia Soledad; Sabé, Anna; Martín, Luna; Segura-Bayona, Sandra; Verde, Gaetano; Aiese Cigliano, Riccardo; Millanes-Romero, Alba; Jerónimo, Celia; Cebrià-Costa, Joan Pau; Nuciforo, Paolo; Simonetti, Sara; Viaplana, Cristina; Dienstmann, Rodrigo; Oliveira, Mafalda; Peg, Vicente; Stracker, Travis H; Arribas, Joaquín; Canals, Francesc; Villanueva, Josep; Di Croce, Luciano; García de Herreros, Antonio; Tian, Tian V; Peiró, Sandra.
Afiliación
  • Serra-Bardenys G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Blanco E; Institut Bonanova FP Sanitaria, Consorci Mar Parc de Salut de Barcelona, Spain.
  • Escudero-Iriarte C; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain.
  • Serra-Camprubí Q; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Querol J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pascual-Reguant L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Morancho B; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain.
  • Escorihuela M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tissera NS; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Sabé A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martín L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Segura-Bayona S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Verde G; The Francis Crick Institute, London, UK.
  • Aiese Cigliano R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Millanes-Romero A; Sequentia Biotech SL, Barcelona, Spain.
  • Jerónimo C; Institute for Research in Biomedicine (IRB Barcelona) and Barcelona Institute of Science and Technology, Spain.
  • Cebrià-Costa JP; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Spain.
  • Nuciforo P; Institut de Recherches Cliniques de Montréal, Canada.
  • Simonetti S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Viaplana C; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Oliveira M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Peg V; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Stracker TH; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Arribas J; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Canals F; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Villanueva J; Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Barcelona, Spain.
  • Di Croce L; Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • García de Herreros A; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Tian TV; Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
  • Peiró S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
FEBS J ; 291(11): 2423-2448, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38451841
ABSTRACT
Oxidation of histone H3 at lysine 4 (H3K4ox) is catalyzed by lysyl oxidase homolog 2 (LOXL2). This histone modification is enriched in heterochromatin in triple-negative breast cancer (TNBC) cells and has been linked to the maintenance of compacted chromatin. However, the molecular mechanism underlying this maintenance is still unknown. Here, we show that LOXL2 interacts with RuvB-Like 1 (RUVBL1), RuvB-Like 2 (RUVBL2), Actin-like protein 6A (ACTL6A), and DNA methyltransferase 1associated protein 1 (DMAP1), a complex involved in the incorporation of the histone variant H2A.Z. Our experiments indicate that this interaction and the active form of RUVBL2 are required to maintain LOXL2-dependent chromatin compaction. Genome-wide experiments showed that H2A.Z, RUVBL2, and H3K4ox colocalize in heterochromatin regions. In the absence of LOXL2 or RUVBL2, global levels of the heterochromatin histone mark H3K9me3 were strongly reduced, and the ATAC-seq signal in the H3K9me3 regions was increased. Finally, we observed that the interplay between these series of events is required to maintain H3K4ox-enriched heterochromatin regions, which in turn is key for maintaining the oncogenic properties of the TNBC cell line tested (MDA-MB-231).
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Heterocromatina / Histonas / Neoplasias de la Mama Triple Negativas / Aminoácido Oxidorreductasas Idioma: En Revista: FEBS J Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Heterocromatina / Histonas / Neoplasias de la Mama Triple Negativas / Aminoácido Oxidorreductasas Idioma: En Revista: FEBS J Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article